Edimer Pharmaceuticals is currently in Phase 2 clinical trial of EDI200 as a potential treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). XLHED is a rare orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations.
Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisors. The company is based in Cambridge, Massachusetts.
Stay Informed. Stay Connected. Join the XLHED Network today.